Before the advent of targeted therapy, ALK-positive advanced non-small cell lung cancer (NSCLC) typically progressed rapidly, with a high incidence of brain metastases and limited median survival. Treatment strategies primarily relied on passive control through…
Epidermal growth factor receptor EGFR–targeted drugs represent a cornerstone in the treatment of advanced non–small cell lung cancer (NSCLC) harboring EGFR gene mutations. EGFR mutations are a major category of lung cancer biomarkers. NSCLC is…
DengYueMed is a licensed Pharmaceutical Distributor in Hong Kong providing wholesale pharmaceuticals, global drug export, GDP-compliant distribution, and cold chain supply solutions for international markets. For regional agents, cross-border medical platforms, and medical institutions, the…
The top 5 rare disease companies include Roche, Novartis, Johnson & Johnson, AstraZeneca, and Vertex Pharmaceuticals. These industry leaders are advancing orphan drugs, gene therapy, and innovative treatments for patients with rare diseases worldwide. In…
Abbisko’s Pimicotinib for tenosynovial giant cell tumor (TGCT) is an oral CSF-1R inhibitor developed by Abbisko Therapeutics for the treatment of symptomatic or unresectable TGCT. It became China’s first approved Class-1 CSF-1R inhibitor in 2025.…
How do pharmaceutical wholesalers work? Pharmaceutical wholesalers source medicines from approved suppliers, manage quality control and storage, coordinate cold chain logistics, handle international exports, and support global pharmaceutical procurement through reliable supply chain services. As…
As antibiotic resistance continues to worsen worldwide, the pharmaceutical industry is searching for next-generation anti-infective solutions. Among the most promising approaches, antimicrobial peptides against antibiotic resistance are emerging as a major focus of research and…
Liver cancer is one of the most serious and life-threatening cancers worldwide. According to the International Agency for Research on Cancer (IARC), liver cancer remains one of the leading causes of cancer-related deaths globally. As…
RNA therapeutics for cardiovascular disease are emerging as a transformative strategy for long-term disease management. Unlike traditional treatments that target proteins after they are produced, RNA-based therapies such as siRNA and antisense oligonucleotides act at…
Over the past two decades, the China API industry has evolved into a foundational pillar of the global pharmaceutical ecosystem. 🌏 HongKong DengYue Medicine continues to track global demand shifts in the china api industry…
The excitement surrounding antibody-drug conjugates (ADCs) has not yet faded, but a new frontier is already capturing the attention of global pharmaceutical giants. 🔥 Recently, Johnson & Johnson announced a $1 billion acquisition of Firefly…
More and more overseas patients are beginning to explore China’s innovative drug resources in search of new treatment opportunities. However, for international patients, the real challenge is often not whether the medicines exist, but rather:…
